switching to biosimilars: a conversation with peter taylor
Published 7 years ago • 758 plays • Length 53:30
Download video MP4
Download video MP3
Similar videos
-
4:21
biosimilars and rheumatoid arthritis | making the switch
-
2:46
switching to biosimilars (with subtitles).
-
2:41
switching to biosimilars 2021
-
2:16:17
biosimilars stakeholders event 2014
-
27:00
professor peter taylor's nras members day 2012 presentation part 2
-
1:08
the impact of switching from a reference biologic to a biosimilar
-
0:59
how do i talk to my doctor about starting a biosimilar?
-
0:57
what's the difference between a biologic and a biosimilar?
-
27:32
professor peter taylor's nras members day 2012 presentation part 1
-
38:15
biosimilars and biologics
-
39:16
professor angela thomas: "regulation of biologics & biosimilars"
-
4:09
better understanding biosimilar medications
-
3:31
treatment persistence and switching patterns of an adalimumab biosimilar
-
3:45
what are biosimilars? how do they work for arthritis?
-
1:31:06
biologics & biosimilars: insights for patients & physicians
-
2:02
dr. arthur kavanaugh on biosimilars and drug switching
-
1:40
biosimilars: an alternative to expensive biologic medicines
-
6:18
fda approves of biosimilar to infliximab – ibd in the news
-
1:23
dr. rule on rituximab biosimilar use in the uk
-
4:18
what is a biosimilar? biosimilars explained by a doctor and pharmacist
-
7:25
synthetic biology: this will change everything: christopher bradley at tedxnyu
-
11:03
biosimilars in the us and beyond
-
4:20
fda approves biosimilar to humira – ibd in the news
-
10:00
ibd clinical case: the process of switching from a reference biologic to a biosimilar
-
10:00
navigating biosimilars: biologics and biosimilars (gray line)
-
1:09
kalveer flora, mpharm: patient response to switching to biosimilar adalimumab
-
17:46
the conversion: taylor halversen at tedxusu
-
1:09:11
biosimilars: what you need to know
-
1:35
biosimilars: safety & efficacy
-
4:18
ghlf - biologics and biosimilars - a multi-stakeholder perspective
-
35:31
understanding biosimilars: how the availability of biosimilars will impact clinical practice
-
0:53
switching to a biosimilar - canadian biosimilars forum
-
0:40
transition to biosimilar conversation
-
1:57
pfizer canada responds - understanding biologic and biosimilar treatments
-
5:13
biologics, biosimilars and generics for the treatment of retinal disease
-
39:48
optimizing biosimilars for safe and effective management of imids
-
11:24
adalimumab biosimilar bi 695501 (cyltezo®; adalimumab-adbm) in rheumatoid arthritis
-
59:22
biologics and biosimilars litigation update
-
10:13
fda approval of biosimilar, proposed change in us drug prices, and 2018 asco presscast
-
3:16
how to safely, effectively substitute biological medicines
-
8:03
navigating biosimilars: extrapolation, naming, substitution (blue line)
-
16:32
the rheumatology perspective - ihe biosimilars forum
-
57:41
webinar: biologics & biosimilars
-
0:25
the power of biosimilars: the benefits of fda-approved biologics #shorts
-
6:03
arthritis research education series ep. 11 - biosimilars unpacked
-
2:31
care update on biosimilars: nor-switch and beyond
-
57:53
biosimilars: what you need to know
-
48:42
will biosimilars change the treatment paradigm in psoriasis?
-
42:33
complexities in routine cultures: common conundrums in bacterial id and ast*
-
0:41
making an informed decision: the key questions to ask when considering a biosimilar #shorts
-
1:23
patients’ experiences in receiving information about biologics – video abstract id 153741
-
1:35:38
cardiovascular risk in rheumatoid arthritis and q&a session – professor george kitas
-
17:57
understanding biosimilars: differences between biosimilars and reference products
-
57:20
brown bag series:feminist organising for systems change & twenty-three languages & digital inclusion
-
0:16
biosimilar medications: as identical twins explain, biosimilars have the same benefits (15 sec.)
-
5:07
biosimilar interchangeability in practice
-
18:16
vender on psoriasis s01 e06 - biologics use and biosimilars
-
32:05
a synthesis born of necessity unlocks a nano-world of wonders
-
4:36
the extrapolation of biosimilar indications: understand the practical implications
-
56:46
latest scientific insights on why and how we should invest in the early years | learning exchange
-
19:44
professor chiara bonini - novel gene editing technology – the application of crispr - pt. 1
-
5:48
comparison of biologics to biosimilars versus generics
-
17:34
biosimilars 101: what are biosimilars and why should you care?
-
2:47
biologics vs. biosimilars: what’s the difference?
-
4:05
from biologics to biosimilars: current status and future challenges
-
11:46
eular interview: need to know: biosimilars
-
4:33
biosimilars
-
1:00
dr. hershman on the equivalency of biosimilars and biologics
-
40:51
biologics and biosimilars interchangeability: a deep dive with industry experts
-
2:52
what's health canada saying about biosimilars?
-
4:05
the future of biosimilar medicines
-
30:04
biosimilars: what we need to know
-
1:33:50
lfc lecture: anne larilahti (a leadership for change video)
-
13:32
01 introduction to biosimilars
-
0:47
empowering change managers with technology - with johnson & johnson, siemens healthineers & velera
-
1:06:22
arthritis research education series ep. 11 webinar - biosimilars unpacked
-
3:51
investing with a gender lens: prof. sarah kaplan with eve ellis of morgan stanley
-
2:21
what are biosimilars?
-
3:51
let's talk biosimilars
-
2:00
helen's story — she knows she can rely on biosimilars
-
2:34
what is a biosimilar?
-
7:33
a 'wake-up' call to resolve uk cancer drug access
-
2:24
the benefits of biosimilars
-
1:47
understanding biosimilars - for ibd patients
-
45:46
patient and provider perspectives for biosimilars in ibd and ra - is similar the same?
-
2:03
future of health focus on biosimilars
-
2:02
biologics and biosimilars explained
-
1:01:28
#r2en virtual discussion on "the future of the multilateral order"
-
1:01:23
understanding biosimilars | arthritis talks
-
38:38
considerations in use of biosimilars for gastrointestinal disorders
-
46:32
leveraging technology to transform finance for the new normal
-
3:42
rheumatic diseases: biosimilars vs original biologics
-
1:04:56
biologics and biosimilar definitions and concepts of development
-
4:17
abp 501 biosimilar vs. adalimumab after single transition, papp et al
-
1:21
biologics revolutionized healthcare
-
54:58
arthritis consumer experts' biosimilars in canada webinar
Clip.africa.com - Privacy-policy